Core Viewpoint - American Shared Hospital Services reported a 16% sequential increase in total revenue for Q2 2025, driven by growth in treatment volumes and expansion of services [2][5]. Financial Performance - Q2 2025 revenue reached $7,071,000, a 0.2% increase compared to Q2 2024, attributed to expanded radiation therapy services [6]. - Revenue from direct patient services was $3,500,000, an 11% increase year-over-year, primarily due to acquisitions in Rhode Island and the new facility in Puebla, Mexico [6]. - The medical equipment leasing segment saw an 8% decrease in revenue to $3,571,000, impacted by lower Gamma Knife volumes and the expiration of customer contracts [7]. - Proton beam radiation therapy revenue decreased to $1,921,000 from $2,420,000 in the prior year, reflecting cyclical fluctuations [7]. Treatment Volume and Revenue Breakdown - Radiation therapy revenue for Q2 2025 was $2,541,000, up from $1,892,000 in Q2 2024, driven by the Rhode Island centers and Puebla operations [8]. - Gamma Knife revenue increased by 25% sequentially but decreased by 5% compared to Q2 2024 [5]. - LINAC revenue grew by 7% sequentially and 34% year-over-year [5]. - Proton beam radiation therapy revenue increased by 17% sequentially but decreased by 21% compared to Q2 2024 [5]. Profitability and Loss - The company reported a net loss of $280,000 or $0.04 per share for Q2 2025, compared to a net income of $3,602,000 or $0.55 per diluted share in Q2 2024 [9]. - Adjusted EBITDA for Q2 2025 was $1,701,000, down from $2,010,000 in Q2 2024 [9]. Long-term Growth Strategy - The CEO emphasized a focus on expanding the business model and operational enhancements, with expectations for growth from new installations in Mexico and recent approvals for new treatment centers in Rhode Island [4]. - The company has experienced four consecutive years of revenue growth and three years of sustained profitability, with ongoing strategic acquisitions to bolster growth potential [4]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents totaled $11,331,000, slightly up from $11,275,000 at the end of 2024 [14]. - Shareholders' equity was $24,481,000 or $3.78 per share, down from $25,183,000 or $3.92 per share at the end of 2024 [14].